The Stock Day Podcast welcomed Lexaria Bioscience Corp. the developer of DehydraTECH™, a proprietary drug delivery technology that improves the way active pharmaceutical ingredients enter the bloodstream. CEO of the Company, Chris Bunka, joined Stock Day host Everett Jolly.Jolly began the interview by asking about the Company’s upcoming investor events. “We’ve made a commitment to attend four virtual conferences …
The Stock Day Podcast welcomed Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), the developer of DehydraTECH™, a proprietary drug delivery technology that improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris Bunka, joined Stock Day host Everett Jolly.
Jolly began the interview by asking about the Company’s upcoming investor events. “We’ve made a commitment to attend four virtual conferences starting tomorrow and over the next five weeks,” shared Bunka, adding that the Company will be discussing their antiviral research.
Jolly then commented on a recent press release detailing the Company’s demonstration of improved oral delivery for antiviral drugs. Bunka elaborated on the Company’s patented drug delivery technology, DehydraTECH™. “The technology is very good, and we’ve improved it more than once in the delivery of cannabinoids and in the delivery of nicotine,” said Bunka, noting that the technology delivers these substances in an oral form. “We thought there were some good reasons on paper to think that our technology might work on a certain group of antiviral drugs as well,” explained Bunka.
“We just finished the animal study at a very high level lab in Philadelphia,” he continued. “A week ago we reported the results, and DehydraTECH™ does in fact improve the efficacy with relation to how much of the drugs are actually absorbed into the bloodstream,” shared Bunka.
“This is one of the key components of what our technology does best; we deliver fat soluble drugs more efficiently, and also more rapidly,” said Bunka. “Two of the drugs that we tested on are currently in use and are well understood and successful drugs in the treatment of HIV/AIDS,” said Bunka, adding that these drugs are also being studied for their potential applications for COVID-19. “This is an important development for Lexaria. It is the very early, but still very real, first stage of what you’d like to see of our technology having effectiveness with the antiviral drug market.”
“Can you talk about the testing that is being planned for 2021?” asked Jolly. “We are looking at roughly ten to twelve different sets of additional studies similar to the one we just announced,” explained Bunka. “We are looking at doing mostly animal studies, but also some human tissue work,” he added. Bunka also shared that the Company will be conducting studies involving drugs like Viagra and Cialis, which exhibit molecular similarities to cannabinoids, nicotine, and antiviral drugs. “2021 is going to be our busiest R&D year ever in the history of the company.”
Bunka then elaborated on the potential of DehydraTECH™ in the cannabis market, an industry which struggles with formulating CBD and CBG in a way that can be absorbed efficiently. “We’ve already completed a human clinical study with CBD, and we demonstrated that we deliver over 300% more CBD in the first 30 minutes than standard industry generic compounds.”
Jolly then asked about the possibility of uplisting in the near future. “Absolutely. We’re making great progress,” said Bunka, noting that the Company expects to be completed with this process in January. “We think that’s going to be the most significantly positive impact for our investors in all the years that we’ve been a public company.”
“What’s your thought on the valuation of your company?” asked Jolly. “I will say this, I am still the largest shareholder of the company,” shared Bunka. “I have never sold a share in this company,” he added. “I think the stock is outrageously undervalued and is one of the best opportunities an investor is ever going to see, and that is just my honest opinion.”
To hear Chris Bunka’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/7746394-lexaria-bioscience-corp-discusses-demonstration-of-improved-oral-delivery-for-antiviral-drugs-wi
Lexaria Bioscience Corp.’s (OTCQX: LXRP) (CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out the antiviral research initiatives, receive regulatory approvals or experience positive effects from any antiviral research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling products containing any active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
About The “Stock Day” Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
Stock Day Media
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69735
News Provided by Newsfile via QuoteMedia